P Mannucci

Author PubWeight™ 6.73^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Modern treatment of haemophilia.	Bull World Health Organ	1995	1.35
2	Pharmacokinetics and safety of fibrinogen concentrate.	J Thromb Haemost	2009	1.06
3	Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes.	Neurology	2004	1.02
4	Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.	Haemophilia	2009	0.98
5	Near-patient testing devices to monitor oral anticoagulant therapy.	Br J Haematol	2001	0.86
6	Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.	Haemophilia	2011	0.82
7	Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.	Thromb Haemost	1992	0.78
8	Report on the workshop: Von Willebrand factor and Thrombotic Thrombocytopenic Purpura.	Am J Hematol	2001	0.75
9	Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiency.	Thromb Res	2000	0.75
10	Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes.	Haematologica	1994	0.75
11	Three novel PROC gene lesions causing protein C deficiency.	Clin Genet	1998	0.75